Following the results of the pivotal IMbrave150 trial, the combination of the anti-programmed death ligand-1 (PD-L1) inhibitor atezolizumab and the vascular endothelial growth factor (VEGF) inhibitor bevacizumab has become the new standard of care for first-line treatment of patients with advanced unresectable hepatocellular carcinoma (BCLC B/C). This evidence concerns the gene VEGFA and hepatocellular carcinoma.